Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: A case-series of health-care workers

The Lancet Infectious Diseases

Volumn 15, Issue 11, 2015, Pages 1300-1304

  Jacobs, Michael ^a   Aarons, Emma ^b   Bhagani, Sanjay ^a   Buchanan, Ruaridh ^a   Cropley, Ian ^a   Hopkins, Susan ^a   Lester, Rebecca ^a   Martin, Daniel ^c   Marshall, Neal ^a   Mepham, Stephen ^a   Warren, Simon ^a   Rodger, Alison ^a,c  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; FAVIPIRAVIR; MONOCLONAL ANTIBODY; RALTEGRAVIR; SMALL INTERFERING RNA; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT;

ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG MEGADOSE; EBOLA HEMORRHAGIC FEVER; FUNDING; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HOLLOW BORE NEEDLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTERMEDIATE RISK POPULATION; LOADING DRUG DOSE; LOW RISK POPULATION; MAINTENANCE DRUG DOSE; NEEDLE; PASSIVE IMMUNOTHERAPY; PENETRATING TRAUMA; PHLEBOTOMY; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS TRANSMISSION; WATCHFUL WAITING; AFRICA; FEMALE; HEMORRHAGIC FEVER, EBOLA; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PROCEDURES; UNITED KINGDOM; YOUNG ADULT;

AFRICA, WESTERN; ANTIVIRAL AGENTS; FEMALE; HEALTH PERSONNEL; HEMORRHAGIC FEVER, EBOLA; HUMANS; LONDON; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; POST-EXPOSURE PROPHYLAXIS; RISK ASSESSMENT; YOUNG ADULT;

EID: 84945435445     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00228-5     Document Type: Article

References (27)

1. Ebola situation report World Health Organization, (accessed June 5, 2015). http://apps.who.int/ebola/en/current-situation/ebola-situation-report-3-june-2015.
2. Feldmann H, Jones S, Daddario-DiCaprio K, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3:e2.
3. Marzi A, Feldmann H, Geisbert T, Falzarano D Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef 2011, S1:004.
4. Gunther S, Feldmann H, Geisbert T, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011, 204:S785-S790.
5. Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 2015, 313:1249-1255.
6. Cnops L, Gerard M, Vandenberg O, et al. Risk of misinterpretation of Ebola virus PCR results after rVSV ZEBOV-GP vaccination. Clin Infect Dis 2015, 60:1725-1726.
7. Ebola virus disease: recommendations in the event of accidental exposure to blood or virus Haut Conseil de la Santé Publique, FranceFrance, (accessed May 2, 2015). http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?%20clefr=467.
8. Review of human-to-human transmission of Ebola virus Centers for Disease Control and Prevention, (accessed June 1, 2015). http://www.cdc.gov/vhf/ebola/transmission/human-transmission.html#twenty-seven.
9. Epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus Centers for Disease Control and Prevention, (accessed July 7, 2015). http://www.cdc.gov/vhf/ebola/exposure/risk-factors-when-evaluating-person-for-exposure.html.
10. Franz D, Jahrling P, Friedlander A, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278:399-411.
11. Public health recommendations for returning workers who are asymptomatic contacts of Ebola virus disease Public Health England, (accessed May 2, 2015). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/396911/20150120_Ebola_recommendations_for_returning_workers_who_are_asymptomati.pdf.
12. Ethical considerations for use of unregistered interventions for Ebola virus disease. Report of an advisory panel to WHO World Health Organization, (accessed May 31, 2015). http://www.who.int/csr/resources/publications/ebola/ethical-considerations/en/.
13. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola World Health Organization, (accessed May 31, 2015). http://www.who.int/medicines/ebola-treatment/2015-0218_tables_of_ebola_drugs_updated.pdf?ua=1.
14. Smither S, Eastaugh L, Steward J, Nelson M, Lenk R, Lever M Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014, 104:153-155.
15. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gubther S Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014, 105:17-21.
16. Furuta Y, Gowen B, Takahashi K, Shiraki K, Smee D, Barnard D Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013, 100:446-454.
17. Mentre F, Taburet A-M, Guedi J, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 2014, 15:150-151.
18. West African Ebola epidemic after one year - slowing but not yet under control. N Engl J Med 2015, 372:584-587. WHO Ebola Response Team.
19. Ebola haemorrhagic fever in Zaire 1976. Bull World Health Organ 1978, 56:271-293.
20. Qiu X, Fernando L, Melito P, et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 2012, 6:e1575.
21. Qui X, Audet J, Wong G, et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012, 4:138ra81.
22. Qui X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
23. Audet J, Wong G, Wang H, et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep 2014, 4:6881.
24. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013, 110:1893-1898.
25. Bradfute S, Anthony S, Stuthman S, et al. Mechanisms of immunity in post-exposure vaccination against Ebola virus infection. PLoS One 2015, 10.1371/journal.pone.0118434.
26. Towner J, Rollin P, Bausch D, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004, 78:4330-4341.
27. Faye O, Boelle P-Y, Helleze E, et al. Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study. Lancet Infect Dis 2015, 15:320-326.